BeyondSpring Files 2025 Annual Report on Form 10-K

Core Viewpoint - BeyondSpring Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC, which includes the company's audited consolidated financial statements [1]. Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for high unmet medical needs [3]. - The company's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer (NSCLC) and other indications [3]. - Plinabulin operates through a novel mechanism as a dendritic cell maturation agent, which supports anti-cancer activity and immune modulation, providing a unique approach to enhancing tumor sensitivity to checkpoint inhibitors [3]. Financial Reporting - The annual report on Form 10-K can be accessed on the SEC's website and the company's website under the "Latest Results" section in the Investors area [1]. - The company offers a hard copy of its annual report containing audited consolidated financial statements free of charge to shareholders upon request [2].